Author

François Vergez

Centre National de la Recherche ScientifiqueORCID 0000-0002-0063-4404Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexandre Boudet· 1 shared Alexandre Gay· 1 shared Ambrine SahaliD· 1 shared Anais Granjon· 1 shared André BarucheliD· 1 shared Anne Quillet‐MaryiD· 1 shared Bastien GerbyiD· 1 shared Carine JoffreiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexandre Boudet

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A PTBP1-CDC42 splicing axis regulates leukemia growth and venetoclax sensitivity in acute myeloid leukemia

Margaux Oberling, Mathieu Landry, Yann Aubert, Manon Faivre, Alexandre Gay, Alexandre Boudet, Anais Granjon, Ambrine Sahal, Sarah Bertoli, François Vergez, Véronique Mansat‐De Mas, Christian Récher, Clément Larrue, Laura Poillet-Perez, Jean‐Emmanuel Sarry, , Margherita Ghisi

This study identifies PTBP1-CDC42 splicing regulation as a critical factor in AML growth and venetoclax sensitivity, suggesting a therapeutic combination strategy.

bioRxiv · Aug 26, 2026 · PreprintCancer Biology

Targeting glucocorticoid-induced CD20 activation in preclinical models of B-ALL

Jérémy Bigot, Mathieu Bouttier, Vincent Fregona, Clémence Rouzier, Manon Bayet, Sylvie Hébrard, Naïs Prade, Stéphanie Lagarde, Christine Didier, Laëtitia Largeaud, François Vergez, Anne Quillet‐Mary, Loïc Ysebaert, Cyril Broccardo, André Baruchel, , Bastien Gerby

This study identifies CD20 as an actionable target in B-ALL MRD using PDX models and single-cell RNA sequencing, showing anti-CD20 antibodies can eradicate drug-resistant cells.

bioRxiv · Dec 18, 2025 · PreprintCancer Biology